Navigation Links
CMC Biologics Completes First Stage of Expansion with Addition of Single-Use Facility
Date:8/24/2010

COPENHAGEN, Denmark and SEATTLE, Aug. 24 /PRNewswire/ -- CMC Biologics, a Contract Manufacturing Organization with manufacturing sites in Europe and the USA, today announced the completion of a new state-of-the-art disposable manufacturing facility at its Seattle, WA site.  The addition comes as part of a staged major expansion plan, which will add significant production capacity to its existing facility to accommodate a growing demand for cGMP manufacture of biopharmaceuticals.

(Logo: http://photos.prnewswire.com/prnh/20100824/SF54816LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100824/SF54816LOGO)

The multi-purpose, single-use facility will allow for early-phase clinical manufacture of a range of biopharmaceuticals, including monoclonal antibodies and other mammalian cell culture-based recombinant proteins.  CMC Biologics has partnered with Hyclone to supply the new disposable facility with processing equipment, including a 100L and two 500L single-use bioreactors (SUBs) and disposable mixers. "Disposable technology offers the advantages of increased flexibility and efficiency, decreased cross-contamination risks, and elimination of cleaning, sterilization and other change-over procedures typically associated with traditional steel tank facilities, while providing the same performance," said Andy Walker, Senior Director of Manufacturing.  "Consequently, it provides a cost-effective strategy for reducing the speed to market for many biologics."  Gustavo Mahler, President and Chief Operating Officer, added, "As process yields continue to increase through advances in protein expression, cell culture, and purification technologies, the need for costly high-volume stainless steel tank facilities will decline for some products. We believe this trend will continue to push bioprocessing toward single-use technology."  

For other products where use of disposables is not feasible, CMC Biologics continues to offer its stainless-steel clinical and commercial cGMP manufacturing facility.  They are currently increasing capacity with the addition of a second 3000L bioreactor train, identical to the existing line.  Recent client demand has prompted initial steps in the plan toward build-out of a pre-existing structure anticipated to house two 5000L commercial-ready manufacturing lines.  CMC Biologics has also increased headcount by more than 30% at its Seattle site to support the expansion.

About CMC

CMC Biologics (www.cmcbio.com) is a leading contract development and manufacturing organization that provides fully integrated biopharmaceutical development and manufacturing services to clients around the world, from its facilities in Europe and the USA. The company specializes in custom services for the scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials and in-market production. CMC Biologics' wide range of integrated services includes cell line development using its proprietary CHEF1® system, process development and comprehensive analytical testing. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers both stirred tank and perfusion production processes.  CMC Biologics is located in Copenhagen, Denmark, and Bothell, Washington, near Seattle.


'/>"/>
SOURCE CMC Biologics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Decision Resources Competitive Landscape Seminar Series: Biologics and Biosimilars on September 14, 2010 Will Help Pharmaceutical Companies Understand Market Opportunities for Biologics and Biosimilars
2. New FDLI Monograph Provides Expert Guidance on Selling Pharmaceuticals, Biologics to Federal Government
3. Circle Biologics® Introduces Innovation in Medical Devices
4. Pioneer® Surgical Expands Product Specialists to Support Growing Biologics Business
5. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
6. Bone Biologics Announces Another Major US Patent Issuance for Recombinant Protein Process
7. Clive Dix Appointed as Chairman of Crescendo Biologics
8. Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA)
9. PhRMA Statement Supporting Fair Incentives for Biologics Innovation
10. Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)
11. CMC ICOS Biologics and Implicit Bioscience Ltd Announce IC14 Antibody Manufacturing Agreement and Patent License
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... YORK , April 28, 2016  The blood ... 275 million dollars, according to Kalorama Information and The ... typing, immunoassays and nucleic acid testing.  The healthcare research ... made progress in developing blood collection stations and in ... made in Kalorama Information,s report, Blood Testing ...
(Date:4/28/2016)... Dr. Vivek Ahuja , ... phen Schmidt Join the Growing ... solutions for life sciences, today announced key new leaders have joined ... to a growing business.  This will bolster the company,s safety business ... joined ArisGlobal in the position of Vice President - Safety. George ...
(Date:4/28/2016)... FREMONT, Calif. , April 28, 2016 ... Enterprise Validation Lifecycle Management Solutions (VLMS) today ... products and services for sufferers of chronic ... management System to manage their corporate validation ... been seeking a software solution to manage ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... 2016 , ... For the 10,000 Americans who turn 65 on any given ... overall well-being: mental health. Now, a new book—Staying Sharp For Dummies (Paper; ISBN: 978-1-119-18779-0; ... which can include everything from honing your memory and managing stress to eating healthy ...
(Date:4/28/2016)... ... 2016 , ... Boston Laser is now offering a novel treatment for Keratoconus ... of the application of Riboflavin, a vitamin, to the cornea. This, combined with UV ... cornea to slow the progression of keratoconus. , Keratoconus is the continuous thinning and ...
(Date:4/28/2016)... ... April 28, 2016 , ... The USDA recently released its updated ... latest nutritional science. While there is a lot of information available in the report, ... the April 2016 issue of Harvard Men's Health Watch . , These ...
(Date:4/28/2016)... ... April 28, 2016 , ... Zerorez Franchising Systems, ... March 2-4. The conference featured several collaborative breakout sessions, presentations, an award banquet, ... franchisees felt they were given tools and resources to assist with operational growth ...
(Date:4/28/2016)... ... 2016 , ... It was the five star ratings and excellent reviews by ... Top Rated Atlanta Plastic Surgeon by Find Local Doctors. Dr. ... Specialists, P.C. This recognition is one of many achievements and awards that Dr. Jones ...
Breaking Medicine News(10 mins):